Topics

Companies Related to "approves first biosimilar Roche cancer drug Rituxan https" [Most Relevant Company Matches] RSS

16:14 EDT 20th September 2019 | BioPortfolio

Here are the most relevant search results for "approves first biosimilar Roche cancer drug Rituxan https" found in our extensive corporate database of over 50,000 company records.

Showing "approves first biosimilar Roche cancer drug Rituxan https" Companies 1–25 of 5,800+

Relevant

Roche Diagnostics, Inc.

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes ma...


Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA approval for Inflectr...

Roche Diagnostics GmbH

Nil


Roche NimbleGen

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based ...

Roche Group

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based ...

Roche Applied Science

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based ...

Alvotech

Alvotech is a powerful new player in the field of biopharmaceuticals, where current portfolio assets include biosimilar versions of leading monoclonal antibodies molecules. Alvotech is proud to offer its biologics manufacturing capabilities to its partners and to cooperate in the commercialization of its own developed biosimilar pipeline. Its state of the ...

Therapeutic Proteins International, LLC

TPI is a fully integrated developer and manufacturer of biosimilar recombinant protein and antibody products. Located in Chicago, TPI is exclusively focused on increasing global access to high quality biologic products by bringing safe, cost effective biosimilar products to patients worldwide. TPI’s fully-integrated process, characterization expertise...

Roche Pharmaceuticals

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing innovative products and services that address prevention, diagnosis and treatment of dis...

De Novo Pharmaceuticals

The commercial focus of De Novo is the exploitation of human genomics in drug discovery through in silico drug design. The company attracted £2 million financing in a first VC-backed investment round in April 2000, followed by a second round of funding of £16.75 million in July 2001. Investors in the first round included Avlar Bioventures, Prelude Technology and Cambridge Research and Innovati...

Exelixis Inc.

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a highly...

BioDuro

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quali...

Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") develops, manufactures, and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. The Company's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. VMSI's drug discovery systems are used to accelerate the di...

ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company’s TAP technology uses antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to tumor targets. In addition to the Co...

Nagourney Cancer Institute

The Nagourney Cancer Institute is a clinical research center that has pioneered the study of human tumor tissue for individualized cancer patient drug selection and has facilitated cancer drug discovery.

Biogen Idec

Scientific excellence that achieves new standards of care drives the company's work. 17 products are currently in clinical development addressing a variety of key medical needs.With patients in more than 90 countries, two blockbuster drugs lead Biogen Idec's product lineup:RITUXAN® (rituximab) was discovered by Biogen Idec for the treatment of certain B-cell non-Hodgkin's lymphomas (NHL). The com...

Therapeutic Proteins International

Therapeutic Proteins International, LLC (TPI) is a fully integrated manufacturer of biosimilar recombinant protein products. TPI’s vision is to produce high quality, life-altering biologics accessible and affordable to patients around the globe. The company’s application of its groundbreaking proprietary process and patented manufacturing platfor...

ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a ...

IOmet Pharma

IOmet Pharma Ltd is a privately-held drug discovery company based in Edinburgh, UK. Founded in 2008, IOmet is focused on the development of innovative medicines for the treatment of cancer, with particular emphasis on the fields of cancer immunotherapy and cancer metabolism. IOmet has a team with a proven track record of success in bringing small molecules...

Chugai Pharma Europe Ltd

Chugai Pharmaceutical Co., Ltd is headquartered in Tokyo, Japan. In its home market, Chugai is a household name, with a broad-ranging product portfolio encompassing highly specialised therapeutic antibody biotechnology through over-the-counter medicines to consumer healthcare products.Chugai is currently the 5th ranked pharmaceutical company in Japan in terms of sales, (the world’s second larges...

Celltrion, Inc.

Based in Incheon, Republic of Korea, Celltrion, Inc. is a global biopharmaceutical leader with strong research and development capabilities in biosimilar monoclonal antibodies (mAbs) and novel drugs for various therapeutic areas, including oncology and autoimmune diseases. Founded in 2002, Celltrion focuses on promoting the health and welfare of patients i...

Kosan Biosciences

Kosan Biosciences is an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones. Kosan has built an industry-leading position in Hsp90 inhibitors. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival....

Roche Biosciences

Today Roche Bioscience researchers are focused on the discovery and delivery of new medicines to treat the following diseases:Alzheimer's disease HIV/AIDS Arthritis Incontinence Asthma Osteoporosis Anxiety Overactive bladder Auto-immune disorders Benign prostatic hyperplasia Depression Pelvic hypersensitivity Emphysema and chronic bronchitis Schizophrenia Hepatitis C

Abreos Biosciences

Abreos Biosciences is focused on ligand binding assays for biologic and biosimilar drug development, activity validation, authentication, and precision dosing, as well as massively multiplexed biomarker assays. Abreos has already developed reagents for the detection of several drugs currently available on the market such as rituximab, obinutuzumab, trastuz...


More From BioPortfolio on "approves first biosimilar Roche cancer drug Rituxan https"

Quick Search

Corporate Database Quicklinks